DCDK9-202
DCDK9-202 a potent CDK9 PROTAC degrader with an DC50 value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand ; Blue: CRBN ligand (HY-W248665) ; Black: Linker (HY-N8015) ).
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Caspase; CDK; PARP; PROTACs
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
CC(C)(C1=CN=C(O1)CSC2=CN=C(S2)NC(C3CCN(CC3)C(CCCCCCCN4CC5=C(C4)C=C6C(N(C(C6=C5)=O)C7CCC(NC7=O)=O)=O)=O)=O)C
Molecular Formula
C40H49N7O7S2
Molecular Weight
803.99
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3; Caspase 7; CDK9; Cereblon
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human DMD sgRNA gene knockout kit - Lentiviral human DMD sgRNA gene knockout kit (plasmid)
CDX4 (Caudal Type Homeobox 4) (MaxLight 405) discontinued
Polyclonal Antibody to Transient Receptor Potential Cation Channel Subfamily V, Member 1 (TRPV1)
Polyclonal Antibody to Transient Receptor Potential Cation Channel Subfamily V, Member 1 (TRPV1)